← All organizations
Highest phase reached
Phase 3
First clinical trial
Apr 1, 2013Last known activity
Jan 1, 2026
Timeline
2000s
- Jun 1, 2001
Chipscreen Biosciences, Ltd.— Founded
Drugs by trial phase (37 distinct, 42 trials)
Phase 3 (15 own, 0 via acquisition)
Phase 2 (16 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Indications
Studied for
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- HIV Infections
- Lung Neoplasms
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Multiple Myeloma
- Neoplasms
- Neoplasms, Plasma Cell
- Ovarian Neoplasms
- Small Cell Lung Carcinoma
Recent trials (42)
- NCT07303803CollaboratorPhase 2Jan 1, 2026
- NCT07129382Lead sponsorPhase 1/Phase 2Sep 8, 2025
- NCT06902350Lead sponsorPhase 1May 21, 2025
- NCT06497985Lead sponsorPhase 3Sep 30, 2024
- NCT06492915Lead sponsorPhase 2Aug 1, 2024
- NCT06224595Lead sponsorPhase 1Mar 28, 2024
- NCT06245122Lead sponsorPhase 1Mar 27, 2024
- NCT05979155Lead sponsorPhase 1Oct 31, 2023
- NCT05922709Lead sponsorPhase 1Jul 20, 2023
- NCT05681273Lead sponsorPhase 1Feb 17, 2023
- NCT05603884CollaboratorPhase 2Dec 1, 2022
- NCT05519865Lead sponsorPhase 2Oct 31, 2022
- NCT05515458Lead sponsorPhase 1Sep 30, 2022
- NCT05515445Lead sponsorPhase 1Sep 30, 2022
- NCT05271292Lead sponsorPhase 1/Phase 2Aug 26, 2022
Details
- Founded
- Shenzhen, CN Jun 1, 2001
- Last known activity
- Jan 1, 2026